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Imputation of sequence variants for identification of genetic
risks for Parkinson's disease: a meta-analysis of genome-wide
association studies
International Parkinson Disease Genomics Consortium
Summary
Background—Genome-wide association studies (GWAS) for Parkinson's disease have linked
two loci (MAPT and SNCA) to risk of Parkinson's disease. We aimed to identify novel risk loci
for Parkinson's disease.
Methods—We did a meta-analysis of datasets from five Parkinson's disease GWAS from the
USA and Europe to identify loci associated with Parkinson's disease (discovery phase). We then
did replication analyses of significantly associated loci in an independent sample series. Estimates
of population-attributable risk were calculated from estimates from the discovery and replication
phases combined, and risk-profile estimates for loci identified in the discovery phase were
calculated.
Findings—The discovery phase consisted of 5333 case and 12-019 control samples, with
genotyped and imputed data at 7-689-524 SNPs. The replication phase consisted of 7053 case and
9007 control samples. We identified 11 loci that surpassed the threshold for genome-wide
significance (p<5×10−8). Six were previously identified loci (MAPT, SNCA, HLA-DRB5, BST1,
GAK and LRRK2) and five were newly identified loci (ACMSD, STK39, MCCC1/LAMP3,
SYT11, and CCDC62/HIP1R). The combined population-attributable risk was 60·3% (95% CI
43·7–69·3). In the risk-profile analysis, the odds ratio in the highest quintile of disease risk was
2·51 (95% CI 2·23–2·83) compared with 1·00 in the lowest quintile of disease risk.
Interpretation—These data provide an insight into the genetics of Parkinson's disease and the
molecular cause of the disease and could provide future targets for therapies.
Funding—Wellcome Trust, National Institute on Aging, and US Department of Defense.
Introduction
Parkinson's disease was long thought to be a non-genetic disease. Recent advances in
genotyping have enabled large-scale assessment of genetic risk factors associated with
Correspondence to: Dr Andrew Singleton, Laboratory of Neurogenetics, 35 Convent Drive, Bethesda, MD 20837, USA
singleta@mail.nih.gov.
Contributors
MAN, VP, JS-S, MM, JH, PH, AB, TG, ABS, and NWW designed the study. MAN, MM, JH, PH, AB, TG, ABS, and NWW obtained
funding. DGH, MSh, U-MS, JS-S, CS, SL, SS, KS, MM, JH, PH, AB, TG, ABS, and NWW collected samples. KS, MM, JH, PH, AB,
TG, ABS, and NWW supervised the study. MAN, VP, MSh, U-MS, MSa, JS-S, CS, SL, MM, AB, and ABS did the data analysis and
data management.
Conflicts of interest
KSt has received grants from deCODE. JH has received consulting fees or honoraria from Eisai and his institute has received
consulting fees or honoraria from Merck-Serono. TG has received consultancy fees from Cephalon and Merck-Serono; grants from
Novartis; payments for lectures including service on speakers' bureaus from Boehringer Ingelheim, Merck-Serono, UCB, and Valeant;
and holds patents NGFN2 and KASPP. MAN, VP, DGH, MSh, U-MS, MSa, JS-S, CS, SL, SS, KS, MM, PH, ABr, ABS, and NWW
declare that they have no conflicts of interest.
NIH Public Access
Author Manuscript
Lancet. Author manuscript; available in PMC 2013 June 30.
Published in final edited form as:
Lancet. 2011 February 19; 377(9766): 641–649. doi:10.1016/S0140-6736(10)62345-8.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Parkinson's disease. MAPT and SNCA 1, 2, 3, 4 and 5 have consistently shown associations in
genome-wide association studies (GWAS). BST1, LRRK2, GAK, and HLA-
DRB5 1, 2, 3, 5, 6 and 7 have been implicated in some studies but these associations have not
been definitively confirmed.
Although an exciting next step in the genetic study of human disease will be the use of
exome or genome sequencing in adequately powered large-scale population-based studies,
this method is cost prohibitive at present.8 A compromise between array-based and
sequence-based methods is the use of freely available sequence-based resources from the
1000 Genomes Project, which allows imputation of a large number of variants into existing
genotyping studies.
We did a meta-analysis of Parkinson's disease GWAS to investigate the associations of
previously identified loci and identify novel risk loci for Parkinson's disease.
Methods
Study design
Investigators representing four published GWAS 1, 2, 3 and 9 formed a consortium with the
predetermined goal to discover new loci associated with Parkinson's disease by a
prospective meta-analysis of imputed sequence variants (discovery stage). We identified one
additional dataset from the database of genotypes and phenotypes.5 and 10 A secondary
requirement for inclusion of a dataset in this study was the ability to use custom-built
ImmunoChip arrays to do replication analyses in independent sample series (replication
stage). The five included datasets were from the USA National Institute on Aging, UK,
Germany, France, and the USA database of genotypes and phenotypes. 1, 2, 3, 5, 9 and 11
We aimed to assess the biological consequences of risk variants identified in our study by
examining the association between these alleles and both gene expression and DNA
methylation. Our primary interest in these single nucleotide polymorphism (SNP)-based
analyses was to investigate every locus associated with Parkinson's disease and to test
whether the disease-related SNPs were associated with DNA methylation or gene expression
levels. Further, we wanted to test whether the most strongly disease-associated SNPs were
also the most strongly associated quantitative trait locus SNPs.
Data imputation and statistical analysis
After individual sample collection and study-specific quality control (webappendix pp 1–7),
we used a Markov Chain based haplotyper (MACH; version 1.0.16) on every dataset to
impute genotypes for all participants of European ancestry with haplotypes derived from
initial low coverage sequencing of 112 European ancestry samples in the 1000 Genomes
Project (as of August, 2009).12 and 13 For all datasets, data were imputed by a two-stage
design. The first stage generated error and crossover maps as parameter estimates for
imputation on a random subset of 200 samples per study over 100 iterations of the initial
statistical model. We used these parameter estimates to generate maximum likelihood
estimates of allele numbers per SNP on the basis of reference haplotypes for the datasets
during the second stage of the imputation. SNPs with RSQR quality estimates of less than
0·30 as indicated by MACH were excluded from analyses of the datasets, because imputed
genotypes below this threshold are probably of poor quality.
We did genome-wide dataset analyses at every site with MACH2DAT.12 We used non-
integer allele numbers as a primary predictor of Parkinson's disease in logistic regression
models to account for imputation uncertainty. Webappendix pp 1–7 shows specific details of
analyses of the datasets. Summary statistics from genome-wide association analyses of
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every dataset were included in the meta-analyses. For every dataset, we used basic
covariates of component vectors 1 and 2 from either principal components or
multidimensional scaling analyses of the case-control cohorts to identify random genomic
differences between genotyped data from cases and controls in the discovery phase, which
were used to adjust statistical models for covariates accounting for possible population
substructure. This adjustment was not done in analyses of the UK dataset in the discovery
phase of analyses.
For the replication step, we included the SNPs that passed genome-wide significance (fixed
effects p<1×10−5) and quality control on a custom ImmunoChip array (Illumina, San Diego,
CA, USA) in collaboration with the Sanger Institute (Hinxton, UK). Additionally, we
analysed two GWAS (from the Netherlands and Iceland) after the meta-analysis and
included these in the replication stage by the same imputation procedure. These data were
provided by consortium members who provided the GWAS data after the initial discovery
phase. We included a quality control step in the replication analyses that removed SNPs with
inconsistent results across the datasets (I2>75%). 14 and 15 Webappendix pp 4–8 shows
detailed descriptions of the replication analyses that were done in the five ImmunoChip
replication cohorts (USA, UK, Netherlands, Germany, and France) and two in-silico GWAS
datasets (Iceland and Netherlands).
We did fixed-effects inverse variance-weighted meta-analyses with meta-analysis helper
(METAL),16 and 17 with the standard errors of the β coefficients scaled by the square root of
study-specific genomic inflation factor estimates before combining the summary statistics
across datasets. We calculated genomic control for both individual datasets and the entire
meta-analysis for quality control. Genomic control is often estimated as the deviance of the
median test statistic distribution from the expected null; genomic inflation factors less than
1·05 are the general standard in GWAS.18 We used fixed-effects meta-analyses as the
primary method of discovery and R (version 2.11) to do a secondary random-effects meta-
analysis for every SNP.19 This second analysis is useful to estimate the possible effect of
study heterogeneity on results and to qualitatively infer the effect of study heterogeneity on
replication success and generalisability for similar sample series. We calculated χ2 tests for
heterogeneity (Cochran's Q) with METAL and we generated I2 estimates with R. Meta-
analyses and estimates of study heterogeneity were re-run with PLINK as a quality control
measure.
We calculated risk-profile estimates on the basis of cumulative load of risk alleles for loci
identified in the discovery phase, weighted by the discovery phase effect estimates
(logodds ratio). This profile model was applied to the ImmunoChip genotyped replication
cohorts, and the effects were combined across cohorts by inverse variance weighting.
Population-attributable risk was estimated for the specific genetic contribution to disease of
the risk loci identified. In broad terms, it estimates the decrease in cases of a particular
disease within a population that would occur if the risk factor were removed from that
population. Effect sizes and minor allele frequencies were calculated from joint estimates
from the discovery and replication phases combined, to lessen the overestimation caused by
the so-called winner's curse—a form of ascertainment bias that often occurs in two-stage
GWAS wherein natural genetic variation contributes to a slight overestimation of effect
sizes in the discovery phase.20 Joint estimates were also used because of their large sample
size, which should generate more accurate effect estimates.
DNA methylation values at sites close to the risk variants and the expression of genes within
the risk loci were treated as quantitative traits, and we assessed whether the alleles of SNPs
across the risk loci were associated with either, denoting a quantitative trait locus.
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Webappendix pp 10–13 and a previous study21 provide more detail about the methods used
to map quantitative trait loci. Briefly, we used dense genotype data generated in up to 350
people who had donated brain tissue and were neurologically healthy at the time of death.
DNA methylation and transcript expression were assessed in frozen tissue from both frontal
cortex and cerebellum samples of every brain. We tested the association between any typed
polymorphism and any assayed DNA methylation site or transcript. All SNPs within 1 mb
from the SNPs with the smallest p values per locus with fixed-effects p values less than
1×10−5 were investigated as candidate loci that affect the expression and methylation values
of proximal mRNA transcript probes and CpG methylation sites. With the minor allele as a
reference for directionality, we used linear models to quantify the relation between
quantitative trait loci and risk effect for all the loci that contained significant quantitative
trait locus associations. We used linkage-adjusted Bonferroni correction for significance
(webappendix pp 11–13).
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data
interpretation, or writing of the report. All members of the writing group had full access to
all the data in the study and had final responsibility for the decision to submit for
publication.
Results
The discovery phase included 5333 case and 12-019 control samples, with genotyped and
imputed data at 7-689-524 SNPs (table 1; figure 1). 7053 case and 9007 control samples
were included in analyses in the replication stage. Results of tests across the software
packages METAL, R, and PLINK differed only slightly (data not shown).
We identified 11 loci that surpassed the threshold for genome-wide significance (p<5×10−8;
table 2).18 One locus on chromosome 17 from 18-601-523 to 18-602-998 bp that contained
six SNPs associated with Parkinson's disease in the UK cohort was not included because p
values were not less than 0·1 in any other cohort and I2 was greater than 75%. For
simplicity, we have focussed only on the most significant SNP per locus that met these
criteria, and its nearest gene or genes. However, we do recognise that the most proximal
gene is not necessarily the gene functionally affected by risk alleles and that GWAS identify
loci rather than specific genes. Webappendix pp 15–31 provides more detailed results for
every region.
We confirmed the Parkinson's disease associations at the SNCA and MAPT loci 1, 2, 3, 4 and 5
and at BST1, LRRK2, GAK, and HLA-DRB5 (table 2). 1, 2, 3, 5, 6 and 7 Additionally, we
detected evidence of associations at five new loci (the closest gene to the top SNP at every
loci is ACMSD, STK39, MCCC1/LAMP3, SYT11, and CCDC62/HIP1R). However, two of
these loci (ACMSD and CCDC62/HIP1R) showed moderate evidence of heterogeneity
across populations. Webappendix pp 7–8 provides further details about the replication phase
of analysis. All five novel loci passed a Bonferroni threshold of p<0·0045 (correcting for the
11 SNPs tested in the replication phase) for association in the replication phase.
The SNP at the SYT11 locus is about 650 kb from the known Parkinson's disease risk factor
gene GBA and its pseudogene, in a region of the genome with low recombination.22 To test
whether this proximity might contribute to the possible co-segregation of risk alleles at the
SYT11 locus and GBA risk mutations we analysed data from a subset of patients with
Parkinson's disease who were included in the discovery phase analysis and who were from
the USA, France, and Germany, in whom carriers of the GBA mutation have been
identified. The results of this analysis suggested that the signal at the SYT11 locus is
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independent of GBA mutations (webappendix pp 9–10 and pp 32–33). Similarly, we did an
analysis that controlled for the known common LRRK2 mutation G2019S in the replication
phase, and showed that the association detected in the meta-analysis close to LRRK2 might
be caused by variation independent of this mutation (webappendix pp 9–10 and pp 32–33).
Table 2 shows the combined population-attributable risk estimates. The combined estimate
across all 11 identified loci was 60·3% (95% CI 43·7–69·3). For the MAPT and SNCA loci
alone it was 25·6% (18·7–28·9), which was higher than the previous estimate of about 20%.2
The additional loci identified in this study (ACMSD, STK39, MCCC1/LAMP3, and
CCDC62/HIP1R) had a combined estimate of 46·7% (30·7–56·8).
The odds ratio was 2·5 times higher in the highest quintile of disease risk than in the lowest
quintile of disease risk (table 3). The c index from receiver operator curves in the pooled
cohorts was 0·63.
We identified quantitative trait associations at 18-969 SNPs spread across five of the
identified Parkinson's disease risk loci (summarised in figure 2, with complete results
available from the authors upon request). The MAPT locus had many such associations,
with 95·9% of all associations detected across all tissues and arrays in this region. For the
MAPT locus, risk estimates were positively associated with quantitative trait locus effects,
leading to increased gene expression (cerebellum r2 0·1366; frontal cortex r2 0·8042; both
tissues p<2×10−16). We noted the opposite effect in the methylation quantitative trait loci at
MAPT, with minor alleles associated with increased risk and with decreased methylation
(cerebellum r2 0·9268, p <2×10−16; frontal cortex r2 0·4667, p=3·68×−6). The MAPT locus
showed associations for multiple probes within MAPT and probes within proximal genes,
including ARL17A and PLEKHM1. Methylation quantitative trait loci in the MAPT region
included probes within KIAA1267, LRRC37A, and NSF.
Two SNPs in the ACMSD locus showed substantial associations, with expression levels in
cerebellar tissues denoted by a proximal expression probe against the transcript MCM6,
whose transcription start site is more than 750 kb from either associated SNP; the minor
alleles at this pair of SNPs are associated with increased risk of Parkinson's disease and
decreased gene expression. In samples from the frontal cortex, DNA methylation values at
one CpG site within FGFRL1 were associated with 27 proximal SNPs in the GAK region
(>20 kb from the nearest SNP associated with Parkinson's disease), and all effect estimates
suggested risk of Parkinson's disease and increased methylation (r2 0·9897, p<2×10−16).
The HLA-DRB5 region contained 729 significant quantitative trait locus associations in the
frontal and cerebellar tissue samples. For HLA-DRB5, we recorded an overall result similar
to that identified at MAPT, with minor alleles associated with risk effects and with
decreased DNA methylation (cerebellum r2 0·4037, p=9·67×10−5; frontal cortex r2 0·4977,
p<2×10−16).
In addition to probes within HLA-DRB5, methylation quantitative trait locus associations
were detected within probes tagging CpG sites in BTNL2, HLA-DQB2, and SLC44A4. One
CpG probe in the cerebellum samples was associated with 18 SNPs in the CCDC62/HIP1R
region. We noted a relation between risk alleles and DNA methylation at a CpG site within
GPR109B, for which increased risk estimates were closely associated with more negative
methylation effects (cerebellum r2 0·4977, p<2×10−16).
Both the LRRK2 and SNCA genes play a part in Parkinson's disease; thus, we examined
these loci further for potential quantitative trait loci. Detection of LRRK2 with the array-
based method showed expression that was too low to do an accurate analysis. However, we
identified quantitative trait loci at the SNCA locus, where risk alleles were associated with
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increased SNCA expression. Although evidence suggests a link between SNCA expression
and disease risk,23 the level of significance for this locus was not significant (p=1×10−4)
with the threshold for significance that we set (p<3·55×10−5).
Discussion
SNCA, MAPT, and HLA-DRB5 have been confirmed as risk loci for Parkinson's disease by
previous GWAS 1, 2, 3, 4, 5, 6, 7 and 9 and by our meta-analysis. We have also shown that,
although previous GWAS were individually underpowered to prove the associations
between the BST1, LRRK2, and GAK loci and Parkinson's disease, our meta-analysis and
replication analysis identified an association at these loci (panel). 1, 2, 3, 5, 6 and 9
Panel. Research in context
Systematic review—As part of the International Parkinson Disease Genomics
Consortium we had access to several genome-wide association datasets for Parkinson's
disease, including both published and unpublished studies. To identify other studies, we
searched PubMed with no date restrictions for published genome-wide association studies in
Parkinson's disease with the following terms: Parkinson's disease, genome wide association.
The search returned studies already included through the consortium members.1, 2, 3, 9 and 11
For those studies outside the existing framework of the consortium, we used all studies that
included more than 300-000 single nucleotide polymorphisms and for which the underlying
genetic data were available for download. This resulted in one additional dataset being
added to the meta-analysis.5
Interpretation—Up to now, to our knowledge this study is the largest genetic analysis of
Parkinson's disease undertaken and has confirmed the associations at six previously
implicated loci and also identified five new loci. This study provides evidence that common
genetic variation plays an important part in the cause of Parkinson's disease. We have
confirmed a strong genetic component to Parkinson's disease, which, until recently, was
thought to be completely caused by environmental factors. The genomic loci described show
the rapid pace of growth in the specialty of genome-wide association studies of complex
disease, and the future predictive use of genes identified in such studies.
GWAS investigate loci that often contain several genes and we should be mindful not to
ascribe disease risk to any one gene within this locus in the absence of further biological
evidence. However, the novel loci detected include biologically plausible candidate for
Parkinson's disease risk. ACMSD is associated with picolinic and quinolinic acid
homoeostasis and is a possible therapeutic target for several disorders that affect the CNS.24
The locus identified near STK39 has been associated with autism, hypertension, and
inflammatory status, 25, 26 and 27 although there have been no reports of this locus
contributing to neurodegenerative phenotypes. The LAMP3 locus might partly cause
modulation of neuronal and neurosecretory function in PC12 cell lines.28HLA-DRB5 is
associated with multiple sclerosis, immunocompetence, and histocompatibility. 29, 30 and 31
The association with Parkinson's disease at HLA-DRB5 supports the theory that
inflammatory factors are associated with the pathogenesis of Parkinson's disease.32 The
protein product of HIP1R is functionally involved in intrinsic cell-death pathways and
interacted with huntingtin to modulate polyglutamine-induced neuronal dysfunction in
transgenic worm and mouse models.33 Finally, the association detected at the SYT11 locus
includes a gene that has been investigated previously in a negative mutation screening study
in 393 patients with familial or sporadic Parkinson's disease34 and in a cell biology study
that showed an interaction between the protein products of SYT11 and PARK2 in patients
with Parkinson's disease.35
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The association between genetic variability at the LRRK2 locus and Parkinson's disease is
mechanistically interesting because data suggest that this association is a result of variability
outside the common G2019S mutation, which raises the possibility that splicing or
expression of wild-type LRRK2 might be pathologically important. If this suggestion is
correct, the role of LRRK2 in Parkinson's disease might relate to an exaggeration of its
normal function rather than some gain of abnormal function.
Understanding of the pathobiologically relevant effect of the identified risk variants in
Parkinson's disease is challenging. However, we associated changes in expression and DNA
methylation with risk alleles at five of the identified loci. This work has many caveats, not
least of which is that it is associative and does not imply causality. However, these data do
serve as a launching point for further investigation into the biological basis of Parkinson's
disease.
The absence of predictive capacity in the risk-profile estimates suggests that common
genetic variability at these loci, the small risk estimates per locus in this meta-analysis (and
GWAS-based studies in general), and the inability to include putative functional variants per
locus, do not allow clinically relevant predictive power to be quantified. Additionally, no
environmental factors were included in risk profiling or population-attributable risk
estimates, which might have led to some overestimation of the genetic risk of Parkinson's
disease, because its cause is probably not entirely genetic.
Assumptions are unavoidable when modelling population-attributable risk with data from
GWAS. Thus, we have probably overestimated the genetic component of Parkinson's
disease risk on the basis of these loci alone because bias inherent in using a case-control
study will slightly skew the frequency of risk alleles higher. However, this calculation did
allow us to rank the contribution of every locus to the genetic cause of Parkinson's disease,
and to estimate the possible decrease in the future incidence of Parkinson's disease achieved
by preventative treatments targeted at genetic causes. Risk-profile modelling provides a
conservative estimate of genetic risk and has moderate predictive power. The identification
of additional common and rare risk variants for Parkinson's disease will probably revise our
estimate of the genetic component of disease upward.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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